Liver Kinase B1/AMP-activated Protein Kinase-mediated Regulation by Gentiopicroside Ameliorates P2X7 Receptor-dependent Alcoholic Hepatosteatosis
Overview
Authors
Affiliations
Background And Purpose: Regulating P2X7 receptor-mediated activation of NLRP3 inflammasomes could be a therapeutic strategy to treat alcoholic hepatosteatosis. We investigated whether this process was modulated by gentiopicroside, the main active secoiridoid glycoside from Gentiana manshurica Kitagawa.
Experimental Approach: In vivo models of acute and chronic alcoholic hepatosteatosis were established by intragastrically administered ethanol or using chronic plus binge ethanol feeding of Lieber-DeCarli liquid diet to male C57BL/6 mice. In vitro, HepG2 cells were treated with ethanol. RAW 264.7 macrophages and murine bone marrow-derived macrophages (BMDMs) were stimulated with LPS and ATP.
Key Results: In both the acute and chronic alcohol-induced mouse hepatosteatosis models, gentiopicroside decreased serum aminotransferases and triglyceride accumulation. Up-regulated SREBP1, down-regulated PPARα and phosphorylated acetyl-CoA carboxylase caused by acute and chronic alcohol feeding were modulated by gentiopicroside, through the elevation of LKB1 and AMPK. Suppression of P2X7 receptor-NLRP3 activation by gentiopicroside inhibited IL-1β production. In ethanol-exposed HepG2 cells, gentiopicroside reduced lipogenesis and promoted lipid oxidation via activation of P2X7 receptor-NLRP3 inflammasomes. Genetic or pharmacological blockade of P2X7 receptors enhanced AMPK activity and reduced SREBP1 expression in ethanol-treated HepG2 cells. Gentiopicroside down-regulated P2X7 receptor-mediated inflammatory responses in LPS/ATP-stimulated RAW 264.7 macrophages and BMDMs. IL-1β from macrophages accelerated lipid accumulation in hepatocytes. Depleting macrophages by clodronate liposomes ameliorated alcoholic hepatosteatosis, and it was further alleviated by gentiopicroside.
Conclusions And Implications: Activation of LKB1/AMPK signalling by gentiopicroside was mediated by the P2X7 receptor-NLRP3 inflammasome, suggesting the therapeutic value of blocking P2X7 receptors in the treatment of alcoholic hepatosteatosis.
Ren J, Chen X, Wang H, Yang T, Zhang K, Lei S Acta Pharmacol Sin. 2025; .
PMID: 39779965 DOI: 10.1038/s41401-024-01449-8.
Xie Q, Zeng Y, Zhang X, Yu F Cancer Immunol Immunother. 2024; 73(9):171.
PMID: 38954021 PMC: 11220057. DOI: 10.1007/s00262-024-03748-9.
Gentiopicroside improves non-alcoholic steatohepatitis by activating PPARα and suppressing HIF1.
Huang C, Yong Q, Lu Y, Wang L, Zheng Y, Zhao L Front Pharmacol. 2024; 15:1335814.
PMID: 38515850 PMC: 10956515. DOI: 10.3389/fphar.2024.1335814.
Jiang P, Jiang W, Li X, Zhu Q Appl Biochem Biotechnol. 2024; 196(10):6726-6744.
PMID: 38401043 DOI: 10.1007/s12010-024-04873-y.
Gentiopicroside-An Insight into Its Pharmacological Significance and Future Perspectives.
Antoniadi L, Bartnik M, Angelis A, Wawruszak A, Halabalaki M, Kukula-Koch W Cells. 2024; 13(1).
PMID: 38201274 PMC: 10778152. DOI: 10.3390/cells13010070.